BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12778772)

  • 21. Fabry disease.
    Levin M
    Drugs Today (Barc); 2006 Jan; 42(1):65-70. PubMed ID: 16511611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anderson-Fabry disease: a protean clinical behavior and a chance diagnosis.
    Amico L; Visconti G; Amato A; Azzolina V; Sessa A; Li Vecchi M
    J Nephrol; 2005; 18(6):770-2. PubMed ID: 16358237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neurological manifestations of Fabry disease].
    Mendióroz M; Fernández-Cadenas I; Montaner J
    Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fabry disease--whom to treat and when.
    Mehta A
    Clin Ther; 2008; 30 Suppl B():S43-4. PubMed ID: 18395136
    [No Abstract]   [Full Text] [Related]  

  • 25. A diagnosis of Fabry gastrointestinal disease by chance: a case report.
    Feriozzi S; Torre ES; Ranalli TV; Cardello P; Morrone A; Ancarani E
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):163-5. PubMed ID: 17273003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful desensitization to agalsidase beta after anaphylaxis.
    Talreja N; Butt A; Valle RL; Fox RW; Lockey RF
    Ann Allergy Asthma Immunol; 2014 Jan; 112(1):71-2. PubMed ID: 24331397
    [No Abstract]   [Full Text] [Related]  

  • 27. Enzyme replacement therapy of Fabry disease.
    Clarke JT; Iwanochko RM
    Mol Neurobiol; 2005 Aug; 32(1):43-50. PubMed ID: 16077182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety.
    Beck M
    Expert Opin Biol Ther; 2009 Feb; 9(2):255-61. PubMed ID: 19236256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trial for Fabry disease faces continuing hurdles.
    Silversides A
    CMAJ; 2009 Nov; 181(11):E251-2. PubMed ID: 19825933
    [No Abstract]   [Full Text] [Related]  

  • 30. [Fabry disease (cardiac lysosomal storage disease) associated with heart failure].
    Takenaka T; Tei C
    Nihon Rinsho; 2007 May; 65 Suppl 5():460-4. PubMed ID: 17571419
    [No Abstract]   [Full Text] [Related]  

  • 31. [Angiokeratoma corporis diffusum universale (Fabry disease)].
    Frank J; Jansen-Genzel W; Lentner A; Wienert V
    Hautarzt; 1996 Oct; 47(10):776-9. PubMed ID: 9036128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme.
    Bodensteiner D; Scott CR; Sims KB; Shepherd GM; Cintron RD; Germain DP
    Genet Med; 2008 May; 10(5):353-8. PubMed ID: 18496035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy.
    Germain DP
    Clin Ther; 2007; 29 Suppl A():S17-8. PubMed ID: 17580237
    [No Abstract]   [Full Text] [Related]  

  • 34. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.
    Oqvist B; Brenner BM; Oliveira JP; Ortiz A; Schaefer R; Svarstad E; Wanner C; Zhang K; Warnock DG
    Nephrol Dial Transplant; 2009 Jun; 24(6):1736-43. PubMed ID: 19293136
    [No Abstract]   [Full Text] [Related]  

  • 36. Early detection of Fabry disease: cardiac cases.
    Weidemann F; Strotmann J
    Clin Ther; 2008; 30 Suppl B():S46. PubMed ID: 18395138
    [No Abstract]   [Full Text] [Related]  

  • 37. [What is new in Fabry disease?].
    Lidove O
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S296-7. PubMed ID: 17964003
    [No Abstract]   [Full Text] [Related]  

  • 38. Shire drops 'emergency' Fabry's disease drug.
    Fox JL
    Nat Biotechnol; 2012 Jun; 30(6):478. PubMed ID: 22678371
    [No Abstract]   [Full Text] [Related]  

  • 39. Agalsidase alfa: a review of its use in the management of Fabry disease.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.
    Desnick RJ
    Expert Opin Biol Ther; 2004 Jul; 4(7):1167-76. PubMed ID: 15268683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.